Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies

Company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression Portfolio comprises three targets, each of which is measurable in plasma and correlates with disease severity Proceeds will advance programs into cl... Biopharmaceuticals, Venture Capital Mediar Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news